Protagonist Therapeutics (PTGX) Competitors $58.94 +0.08 (+0.14%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. SMMT, RDY, ASND, VTRS, QGEN, BBIO, ROIV, VRNA, ELAN, and MRNAShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Its Competitors Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen BridgeBio Pharma Roivant Sciences Verona Pharma PLC American Depositary Share Elanco Animal Health Moderna Protagonist Therapeutics (NASDAQ:PTGX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation. Which has preferable valuation & earnings, PTGX or SMMT? Protagonist Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$434.43M8.39$275.19M$0.7083.73Summit TherapeuticsN/AN/A-$221.32M-$1.01-18.43 Which has more volatility and risk, PTGX or SMMT? Protagonist Therapeutics has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.02, meaning that its stock price is 202% less volatile than the S&P 500. Do analysts prefer PTGX or SMMT? Protagonist Therapeutics presently has a consensus target price of $67.73, indicating a potential upside of 15.55%. Summit Therapeutics has a consensus target price of $33.79, indicating a potential upside of 81.47%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.09Summit Therapeutics 3 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65 Is PTGX or SMMT more profitable? Protagonist Therapeutics has a net margin of 24.88% compared to Summit Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 8.12% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics24.88% 8.12% 7.41% Summit Therapeutics N/A -208.64%-181.28% Does the media favor PTGX or SMMT? In the previous week, Summit Therapeutics had 2 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 28 mentions for Summit Therapeutics and 26 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.10 beat Summit Therapeutics' score of 0.86 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 10 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in PTGX or SMMT? 98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryProtagonist Therapeutics beats Summit Therapeutics on 12 of the 16 factors compared between the two stocks. Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.65B$3.11B$5.75B$10.27BDividend YieldN/A2.32%5.73%4.60%P/E Ratio83.8521.4175.1826.37Price / Sales8.39240.50457.0688.69Price / Cash13.0344.4425.8129.91Price / Book5.179.6113.256.28Net Income$275.19M-$53.20M$3.29B$270.67M7 Day Performance4.31%0.18%0.72%2.79%1 Month Performance4.53%4.02%4.58%6.01%1 Year Performance24.65%9.21%73.44%26.05% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics2.379 of 5 stars$58.94+0.1%$67.73+14.9%+25.2%$3.67B$434.43M84.23120News CoveragePositive NewsAnalyst ForecastAnalyst RevisionSMMTSummit Therapeutics3.0865 of 5 stars$18.94+1.8%$33.79+78.4%-40.7%$14.07BN/A-18.75110RDYDr. Reddy's Laboratories2.2911 of 5 stars$14.65-0.5%$16.95+15.7%-8.9%$12.23B$3.81B22.2027,811News CoveragePositive NewsASNDAscendis Pharma A/S3.1839 of 5 stars$195.58-1.1%$244.36+24.9%+64.0%$11.97B$490.75M-37.901,017Positive NewsVTRSViatris1.5976 of 5 stars$9.96-2.1%$10.40+4.4%-14.6%$11.61B$14.74B-3.4332,000QGENQiagen4.443 of 5 stars$45.30-1.7%$49.69+9.7%+0.5%$10.07B$1.98B26.765,765BBIOBridgeBio Pharma4.4423 of 5 stars$51.21-2.6%$63.94+24.9%+95.6%$9.79B$221.90M-12.52400Analyst ForecastROIVRoivant Sciences3.1479 of 5 stars$14.08-2.3%$17.67+25.5%+17.9%$9.61B$29.05M-20.11860Positive NewsVRNAVerona Pharma PLC American Depositary Share2.3109 of 5 stars$106.43+0.0%$109.00+2.4%+257.4%$9.21B$42.28M-107.5030Positive NewsELANElanco Animal Health2.6297 of 5 stars$18.52-1.4%$17.33-6.4%+28.0%$9.20B$4.44B21.539,000Positive NewsMRNAModerna4.5369 of 5 stars$23.51-7.4%$42.88+82.4%-65.6%$9.15B$3.24B-3.125,800High Trading Volume Related Companies and Tools Related Companies Summit Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Qiagen Alternatives BridgeBio Pharma Alternatives Roivant Sciences Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Moderna Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTGX Stock Alerts